影像学辅助评估新型组蛋白去乙酰化酶抑制剂对去势抵抗性前列腺癌的抗肿瘤疗效
本研究在22Rv1去势抵抗性前列腺癌(CRPC)细胞及异种移植模型中比较新型HDAC抑制剂CN133与SAHA的疗效,并用[11C]Martinostat和[18F]FDG PET/CT监测治疗反应。CN133使肿瘤体积较安慰剂缩小50%,细胞增殖、侵袭和迁移实验中的效力约为SAHA的100倍,机制与HDAC 2和3蛋白表达下降抑制AR信号通路有关。
要点
- CN133治疗使22Rv1异种移植瘤体积较安慰剂缩小50%,疗效优于SAHA。
- [11C]Martinostat PET可识别前列腺癌早期病灶并监测CN133疗效。
- CN133抗肿瘤机制为降低HDAC 2和3蛋白表达、抑制AR信号通路活性。
核心结论
- CN133为前列腺癌治疗提供新型表观遗传学途径,[11C]Martinostat PET/CT有望检测前列腺癌早期并监测CN133疗效,结果可能推动未来人体试验。
研究设计与样本
- 在22Rv1去势抵抗性前列腺癌异种移植模型和22Rv1细胞中比较CN133与SAHA的效果。
- 用[11C]Martinostat和[18F]FDG PET/CT对荷22Rv1异种移植瘤小鼠在21天安慰剂或CN133(1 mg/kg)治疗前后成像并测量摄取。
- 通过qPCR、western blot和ChIP-qPCR研究CN133抗肿瘤机制。
主要发现
- CN133治疗使肿瘤体积较安慰剂缩小50%,在该临床前模型中疗效优于SAHA治疗。
- [11C]Martinostat PET成像可识别前列腺癌早期病灶,并可用于监测CN133在CRPC中的治疗效果。
- 细胞增殖、侵袭和迁移实验中,CN133效力约为SAHA治疗的100倍。
- CN133抗肿瘤机制为通过降低HDAC 2和3蛋白表达抑制AR信号通路活性。
局限性
- 原文结论指出这些结果可能推动未来人体试验,未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Castration-resistant prostate cancer (CRPC) is the most common cause of death in men. The effectiveness of HDAC inhibitors has been demonstrated by preclinical models, but not in clinical studies, probably due to the ineffectively accumulation of HDACI in prostate cancer cells. The purpose of this work was to evaluate effects of a novel HDACI (CN133) on CRPC xenograft model and 22Rv1 cells, and develops methods, PET/CT imaging, to detect the therapeutic effects of CN133 on this cancer. METHODS: We designed and performed study to compare the effects of CN133 with SAHA on the 22Rv1 xenograft model and 22Rv1 cells. Using PET/CT imaging with [11C] Martinostat and [18F] FDG, we imaged mice bearing 22Rv1 xenografts before and after 21-day treatment with placebo and CN133 (1 mg/kg), and uptake on pre-treatment and post-treatment imaging was measured. The anti-tumor mechanisms of CN133 were investigated by qPCR, western blot, and ChIP-qPCR. RESULTS: Our data showed that the CN133 treatment led to a 50% reduction of tumor volume compared to the placebo that was more efficacious than SAHA treatment in this preclinical model. [11C] Martinostat PET imaging could identify early lesions of prostate cancer and can also be used to monitor the therapeutic effect of CN133 in CRPC. Using pharmacological approaches, we demonstrated that effects of CN133 showed almost 100-fold efficacy than SAHA treatment in the experiment of cell proliferation, invasion, and migration. The anti-tumor mechanisms of CN133 were due to the inhibition of AR signaling pathway activity by decreased HDAC 2 and 3 protein expressions. CONCLUSION: Taken together, these studies provide not only a novel epigenetic approach for prostate cancer therapy but also offering a potential tool, [11C] Martinostat PET/CT imaging, to detect the early phase of prostate cancer and monitor therapeutic effect of CN133. These results will likely lead to human trials in the future.
引用
- Chen Z, Wang X, Yang X, et al. Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32592040. doi:10.1007/s00259-020-04896-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。